Head-To-Head Contrast: Insulet (NASDAQ:PODD) & PROCEPT BioRobotics (NASDAQ:PRCT)

PROCEPT BioRobotics (NASDAQ:PRCT) and Insulet (NASDAQ:PODD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of current recommendations and price targets for PROCEPT BioRobotics and Insulet, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	0	1	6	0	2.86
Insulet	0	3	13	0	2.81

PROCEPT BioRobotics currently has a consensus target price of $97.86, indicating a potential upside of 36.73%. Insulet has a consensus target price of $272.81, indicating a potential downside of 2.58%. Given PROCEPT BioRobotics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe PROCEPT BioRobotics is more favorable than Insulet.

Earnings & Valuation

This table compares PROCEPT BioRobotics and Insulet”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$136.19 million	27.42	-$105.90 million	($1.95)	-36.70
Insulet	$1.70 billion	11.57	$206.30 million	$5.84	47.95

Insulet has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

PROCEPT BioRobotics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Insulet has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.

Institutional & Insider Ownership

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by company insiders. Comparatively, 0.5% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares PROCEPT BioRobotics and Insulet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-50.07%	-38.57%	-26.06%
Insulet	21.22%	27.98%	9.16%

Summary

Insulet beats PROCEPT BioRobotics on 9 of the 14 factors compared between the two stocks.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.